Barbara Leggett

Dr. Barbara Leggett


Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2006 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DWDaniel J Weisenberger
Daniel J Weisenberger
KSKimberly D Siegmund
Kimberly D Siegmund
MCMihaela Campan
Mihaela Campan
JYJoanne P. Young
Joanne P. Young
TLTiffany I Long
Tiffany I Long
PLPeter W Laird
Peter W Laird

15 February 2017 in Nature
Verified
Journal Article
Closed access
AIAustralian Pancreatic Cancer Genome Initiative
Australian Pancreatic Cancer Genome Initiative
ASAldo Scarpa
Aldo Scarpa
DCDavid K. Chang
David K. Chang
Katia NonesKatia Nones
Katia Nones
VCVincenzo Corbo
Vincenzo Corbo
SGSean M. Grimmond
Sean M. Grimmond

1 May 2010 in Gastroenterology
Verified
Journal Article
Closed access
BLBarbara Leggett
Barbara Leggett
VWVicki Whitehall
Vicki Whitehall

9 July 2004 in Gut
Verified
Journal Article
Open access
PDF file
TKT Kambara
T Kambara
LSL A Simms
L A Simms
VWV L J Whitehall
V L J Whitehall
KSKevin Spring
Kevin Spring
CWC V A Wynter
C V A Wynter
BLBarbara Leggett
Barbara Leggett
Background and aims: Mutations in BRAF have been linked with colorectal cancers (CRC) showing high level microsatellite instability (MSI-H). However, the distribution of BRAF mutations in MSI-H cancers remains to be clarified with respect to precursor lesions and the CpG island methylator phenotype (CIMP). Methods: Forty three hyperplastic polyps (HP), nine mixed polyps (MP), five serrated adenomas (SA), 28 conventional adenomas (AD), 18 hereditary non-polyposis colorectal cancers (HNPCC), and 127 sporadic CRC (46 MSI-H and 81 non-MSI-H) were collected from patients undergoing colectomy for either CRC or hyperplastic polyposis. Twenty five of 57 serrated lesions were derived from four patients with hyperplastic polyposis. HP were further subdivided according to recently documented morphological criteria into 27 classical HP and 16 variant lesions described as “sessile serrated adenoma” (SSA). All tumours were screened for BRAF activating mutations. Results: The BRAF mutation was more frequent in SSA (75%) and MP (89%) than in classical HP (19%), SA (20%), and AD (0%) (p<0.0001), and also in sporadic MSI-H cancers (76%) compared with HNPCC (0%) and sporadic non-MSI-H cancers (9%) (p<0.0001). The BRAF mutation was identified more often in CIMP-high serrated polyps (72%) and CIMP-high CRC (77%) than in CIMP-low (30%) and CIMP-negative (13%) polyps (p = 0.002) as well as CIMP-low (18%) and CIMP-negative (0%) CRC (p<0.0001). Conclusions: The BRAF mutation was frequently seen in SSA and in sporadic MSI-H CRC, both of which were associated with DNA methylation. Sporadic MSI-H cancers may originate in SSA and not adenomas, and BRAF mutation and DNA methylation are early events in this “serrated” pathway.

22 January 2013 in Histopathology
Verified
Journal Article
Closed access
PDF file
MBMark Bettington
Mark Bettington
NWNeal Walker
Neal Walker
ACAndrew Clouston
Andrew Clouston
IBIan Brown
Ian Brown
BLBarbara Leggett
Barbara Leggett
VWVicki Whitehall
Vicki Whitehall

1 November 2006 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
KSKevin Spring
Kevin Spring
ZZZhen Zhen Zhao
Zhen Zhen Zhao
RKRozemary Karamatic
Rozemary Karamatic
MWMichael D. Walsh
Michael D. Walsh
VWVicki L.J. Whitehall
Vicki L.J. Whitehall
BLBarbara Leggett
Barbara Leggett